Stocktwits on MSN
Travere Therapeutics, Ligand in focus as FDA set to rule on Filspari next week – first FSGS drug at stake
The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026. ・Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.
Stocktwits on MSN
OGN stock surges 20% pre-market, on track to break 200-DMA – why this buyout report has caught investor attention
Sun Pharma reportedly faces competition from two global conglomerates for Organon. ・The Indian firm reportedly made a non-binding offer for Organon in January. ・Organon reported a debt of $8.64 ...
Travere Therapeutics (NASDAQ:TVTX) Stock, Option Chain Option chain shows key data for Travere Therapeutics's stock options at various strike prices and expiration dates. Traders use this information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results